Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Vaxcyte, Inc. (PCVX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/08/2023 8-K Quarterly results
Docs: "Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update -- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease ; Topline Phase 3 Data Expected in 2025 -- -- VAX-31 Adult Investigational New Drug Application Clearance Expected in Fourth Quarter of 2023; Topline Phase 1/2 Data Expected in 2024 -- -- $1.4 Billion in Cash, Cash Equivalents and Investments as of June 30, 2023, Including Net Proceeds of $545.3 Million from April Public Offering -- SAN CARLOS, Calif., August 8, 2023 – Vaxcyte, Inc. , a clinical-stage vaccine innovation company engineering high..."
05/08/2023 8-K Quarterly results
Docs: "Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update -- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied -- -- Dosed First Participants in Infant Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease -- -- VAX-31 Progressing with Adult Investigational New Drug Application Submission and Subsequent Clearance Announcement Expected in Second Half 2023 and Topline Phase 1/2 Data in 2024 -- -- $949.9 Million in Cash, Cash Equivalents and Investmen..."
04/19/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Sales Agreement, by and between Vaxcyte, Inc. and Jefferies LLC",
"Opinion of Cooley LLP"
02/27/2023 8-K Quarterly results
Docs: "Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -- Company Received U.S. Food and Drug Administration Clearance of VAX-24 Infant Investigational New Drug Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 -- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-24 Phase 2 Study in Adults 65 and Older on Track for Second Quarter 2023 -- -- Positive Topline Results from VAX-24 Phase 1/2 Proof-of-Concept Study in Adults Aged 18-64 Indicate Potential Best-in-Class Profile and Validate Company’s Carrier-Sparing Approach -- -- VAX-31 Progressing with Adult IND Application Expected in Second Half 2023 and Topline Phase 1/2 Data in 2024 -- -- Successfully Raised Approximately $805 Million in Gross Proceeds in Two ..."
12/20/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 -- --Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug Application and Study Initiation Expected in First Half of 2023 -- -- $366.2 Million in Cash, Cash Equivalents and Investments as of September 30, 2022, Excluding Net Proceeds of Approximately $650.7 Million from Recent Public Offe..."
10/26/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/18/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/28/2022 8-K Quarterly results
01/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP"
11/10/2021 8-K Quarterly results
Docs: "Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update"
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/20/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
01/25/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC",
"Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC"
12/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 16, 2020 VAXCYTE, INC. Delaware 001-39323 46-4233385 353 Hatch Drive Foster City, California 94404 Registrant's Telephone Number, Including Area Code: 837-0111 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem..."
11/12/2020 8-K Quarterly results
Docs: "Advanced VAX-24 Manufacturing Activities: Vaxcyte progressed several manufacturing initiatives for VAX-24, including for the good manufacturing practices batches of the 24 polysaccharide antigens and the GMP batches of the 24 conjugate drug substances. • Appointed Romulo Colindres, MD, MPH as Chief Medical Officer: In November 2020, Vaxcyte appointed Romulo Colindres, MD, MPH as Chief Medical Officer. Prior to joining Vaxcyte, Dr. Colindres served in several roles at GlaxoSmithKline Vaccines and most recently served as an independent consultant and advisor to multiple biotechnology companies. From March 2007 to March 2019, Dr. Colindres served in roles of increasing responsibility at GlaxoSmithKline, including Head of Health Outcomes for GSK Vaccines Latin America, Head of Global Ep..."
08/12/2020 8-K Quarterly results
06/16/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 16, 2020 VAXCYTE, INC. Delaware 001-39323 46-4233385 353 Hatch Drive Foster City, California 94404 837-0111 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Sec...",
"Amended and Restated Certificate of Incorporation of Vaxcyte, Inc",
"Amended and Restated Bylaws of Vaxcyte, Inc",
"Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy